This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2025 Feb 13;145(7):655-657.

doi: 10.1182/blood.2024027223.

Mosunetuzumab next up to bat … is it a home run?

Reem Karmali¹, Jane N Winter¹

Affiliations

PMID: 39946154
DOI: 10.1182/blood.2024027223

Editorial

Mosunetuzumab next up to bat … is it a home run?

Reem Karmali et al. Blood. 2025.

. 2025 Feb 13;145(7):655-657.

doi: 10.1182/blood.2024027223.

Authors

Reem Karmali¹, Jane N Winter¹

Affiliation

¹ Northwestern University.

PMID: 39946154
DOI: 10.1182/blood.2024027223

No abstract available

PubMed Disclaimer

Comment on

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, Kuruvilla J, Shadman M, Cheah CY, Dietrich S, Fay K, Ku M, Nastoupil LJ, Wei MC, Yin S, To I, Kaufman D, Kwan A, Penuel E, Bolen CR, Budde LE. Sehn LH, et al. Blood. 2025 Feb 13;145(7):708-719. doi: 10.1182/blood.2024025454. Blood. 2025. PMID: 39447094 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems